MedTrace Logo

EGb 761 in the Syndrome of MCI With Concomitant CVD

NCT04525144 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2022-11-17

No results posted yet for this study

Summary

EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.

Conditions

Interventions

DRUG

Tebonin Forte

Dietary supplement: Gingko biloba EGb 761

Sponsors & Collaborators

  • Dr. Willmar Schwabe GmbH & Co. KG

    collaborator INDUSTRY

  • National Neuroscience Institute

    lead OTHER

Principal Investigators

  • Kok Pin Ng · National Neuroscience Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2025-12-31
Completion
2026-11-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04525144 on ClinicalTrials.gov